The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
Diep Ho
No relevant relationships to disclose
Jessica Huang
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Kim Leitzel
No relevant relationships to disclose
Suhail M. Ali
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Wendy R. Parulekar
No relevant relationships to disclose
Catherine Elizabeth Ellis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Rocco J. Crescenzo
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Liting Zhu
No relevant relationships to disclose
Shakeel Virk
No relevant relationships to disclose
Dora Nomikos
No relevant relationships to disclose
Samuel Aparicio
No relevant relationships to disclose
Karen A. Gelmon
No relevant relationships to disclose
Walter P. Carney
Employment or Leadership Position - Nuclea Diagnostics
Allan Lipton
No relevant relationships to disclose